Literature DB >> 17356833

[Treatment of overactive bladder in elderly and old people].

M Zellner1.   

Abstract

Overactive bladder syndrome is a widespread disorder that leads to considerable impairment of quality of life. Besides behavioural therapy (bladder training), methods used in physiotherapy, electrotherapy and instrumental biofeedback have also proved to be successful approaches to treatment. With their good clinical and urodynamic efficacy, substances with antimuscarinic action at M3 receptors in particular and possibly also at M2 receptors have proved successful as first-line agents for the treatment of overactive bladder (OAB). Despite the frequently high level of suffering and severe impairment of quality of life, however, compliance is poor. Muscarine receptors do have a significant effect on detrusor function, but numerous other mechanisms and receptor entities also play a role. Whether patient acceptance can be significantly increased by the development of selective M-receptor antagonists, improved bladder selectivity or formulating innovations remains to be proven by broad-based clinical testing and independent, comparative, scientific studies. At present, it is not possible to estimate with absolute certainty the risk of an anticholinergic-induced deterioration in cognitive abilities, in particular in elderly individuals. Initial data suggest that primarily M3-selective receptor blockage with darifenacin could be beneficial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356833     DOI: 10.1007/s00120-007-1319-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  16 in total

Review 1.  Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.

Authors:  A J Wein
Journal:  Expert Opin Investig Drugs       Date:  2001-01       Impact factor: 6.206

Review 2.  Muscarinic receptor subtypes and management of the overactive bladder.

Authors:  Christopher R Chapple; Tomonori Yamanishi; Russell Chess-Williams
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

3.  Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.

Authors:  Gary Kay; Thomas Crook; Ludmyla Rekeda; Raul Lima; Ursula Ebinger; Miguel Arguinzoniz; Michael Steel
Journal:  Eur Urol       Date:  2006-04-19       Impact factor: 20.096

4.  Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.

Authors:  Jenelle Foote; Karin Glavind; Georg Kralidis; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

5.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

6.  Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier.

Authors:  C Pakulski; L Drobnik; B Millo
Journal:  Med Sci Monit       Date:  2000 Mar-Apr

7.  Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype.

Authors:  G D'Agostino; M L Bolognesi; A Lucchelli; D Vicini; B Balestra; V Spelta; C Melchiorre; M Tonini
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

8.  The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.

Authors:  R Chess-Williams; C R Chapple; T Yamanishi; K Yasuda; D J Sellers
Journal:  J Auton Pharmacol       Date:  2001 Oct-Dec

9.  Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.

Authors:  P G Gillberg; S Sundquist; L Nilvebrant
Journal:  Eur J Pharmacol       Date:  1998-05-22       Impact factor: 4.432

Review 10.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

Authors:  G Nabi; J D Cody; G Ellis; P Herbison; J Hay-Smith
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.